Volume | 9,049 |
|
|||||
News | - | ||||||
Day High | 1.8393 | Low High |
|||||
Day Low | 1.68 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.79 | 1.68 | 1.8393 | 1.75 | 1.82 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
84 | 9,049 | $ 1.78 | $ 16,102 | - | 0.6797 - 2.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:14:29 | 2 | $ 1.78 | USD |
Protagenic Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.76M | 4.44M | - | 0 | -3.56M | -0.80 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protagenic Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.36 | 1.87 | 1.35 | 1.69 | 20,202 | 0.25 | 18.38% |
1 Month | 0.985 | 1.87 | 0.88 | 1.31 | 19,792 | 0.625 | 63.45% |
3 Months | 0.8896 | 1.87 | 0.7336 | 1.20 | 9,782 | 0.7204 | 80.98% |
6 Months | 1.76 | 1.8854 | 0.6797 | 1.06 | 12,592 | -0.15 | -8.52% |
1 Year | 1.63 | 2.32 | 0.6797 | 1.31 | 9,020 | -0.02 | -1.23% |
3 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 456,421 | -9.39 | -85.36% |
5 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 456,421 | -9.39 | -85.36% |
Protagenic Therapeutics Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |